Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2020 11:20 ET | Source: LIDDS AB

Correction of press release: Liproca Phase IIb study results indicate cancer control

In the press release published today at 08:30 CET a figure was missing in the first bullet list in the press release. The correct bullet should read: “57% of the patients were classified as...
May 19, 2020 02:30 ET | Source: LIDDS AB

Liproca Phase IIb study results indicate cancer control

UPPSALA, SWEDEN – LIDDS AB (publ) announces that final data from the LPC-004 study confirms Liproca® Depot’s potential as a safe and effective anti-androgen treatment for prostate cancer patients that...
May 18, 2020 09:40 ET | Source: LIDDS AB

LIDDS announces positive meeting with the Swedish Medical Products Agency, confirming the Liproca® Depot Phase III study design

UPPSALA, SWEDEN – LIDDS AB (publ) announces that the company has received positive responses from the Swedish Medical Products Agency (MPA) regarding the proposed design of the Phase III study of...
May 14, 2020 11:00 ET | Source: LIDDS AB

Kommuniké från årsstämman i LIDDS

UPPSALA, SWEDEN – Den 14 maj 2020 hölls årsstämma i LIDDS AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades enhälligt. Vid stämman var 405 662...
May 14, 2020 02:45 ET | Source: LIDDS AB

LIDDS Delårsrapport januari – mars 2020

JANUARI – MARS 2020 Nettoomsättningen uppgick till MSEK 0,0 (0,0)Rörelsens kostnader uppgick till MSEK -8,0 (-7,1)Resultatet före och efter skatt uppgick till MSEK -8,0 (-7,1)Resultat per aktie...
April 22, 2020 10:00 ET | Source: LIDDS AB

LIDDS publicerar årsredovisning 2019

UPPSALA, SWEDEN – LIDDS publicerar idag årsredovisningen för verksamhetsåret 2019 Årsredovisningen återfinns på bolagets hemsida, se https://liddspharma.com/investors/#financial-reports. För mer...
April 14, 2020 11:00 ET | Source: LIDDS AB

LIDDS Kallelse till årsstämma i LIDDS AB (publ)

UPPSALA, SWEDEN – Aktieägarna i LIDDS AB (publ), org.nr. 556580-2856, kallas till årsstämma i bolagets lokaler på Uppsala Business Park med besöksadress Rapsgatan 7 i Uppsala torsdagen den 14 maj 2020...
April 01, 2020 02:30 ET | Source: LIDDS AB

Additional patients treated in LIDDS clinical study NZ-DTX-001

UPPSALA, SWEDEN – LIDDS AB (publ) announces that the dose escalation in the Phase I study NZ-DTX is proceeding according to the protocol, with additional patients being treated at a higher dose level...
March 25, 2020 03:30 ET | Source: LIDDS AB

LIDDS announces positive preclinical data for NanoZolid®-TLR9 agonist project

UPPSALA, SWEDEN – LIDDS AB (publ) has performed preclinical studies using a TLR9 agonist formulated with NanoZolid® (NZ-TLR9) showing that a single NZ-TLR9 injection is reducing tumor growth and...
March 05, 2020 02:30 ET | Source: LIDDS AB

LIDDS will participate in Redeye’s Fight Cancer Seminar on March 10

UPPSALA, SWEDEN – LIDDS AB (publ) - LIDDS CEO, Monica Wallter, will present the company at the Redeye Fight Cancer Seminar taking place in Stockholm on March 10, targeting both private and...